Navigation Links
New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products
Date:4/6/2009

MORRIS PLAINS, N.J., April 6, 2009 New head-to-head clinical trial results demonstrate that REACH ULTRACLEAN Toothbrush and Floss deliver superior plaque removal. The five studies conducted by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc., and presented today during the 87th General Session and Exhibition of the International Association for Dental Research in Miami collectively found:

  • REACH ULTRACLEAN Floss removes up to two times more plaque than Glide* floss products. i
  • REACH ULTRACLEAN Toothbrush removes more plaque and provides improved gum health versus the Colgate 360** toothbrush. The REACH ULTRACLEAN Toothbrush also removes up to 90 percent of plaque in places that are hard to reach.ii

"The results of the clinical trials for the REACH ULTRACLEAN Toothbrush and Floss help set a new standard for the oral care tools patients use in the fight against plaque," said Sylvia Santos, RDH, MS, Associate Director, R&D, Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc. "Through innovative design and unmatched cleaning technology, we continue to help patients achieve cleaner, healthier mouths."

About the Clinical Studies

Four randomized, observer-blind, three-way crossover and controlled studies were conducted for the REACH ULTRACLEAN Floss to determine dental plaque removal efficacy by flossing. The results demonstrate that REACH ULTRACLEAN Floss removes up to two times more interproximal plaque than Crest Glide Original Mint, Crest Glide Deep Clean, Crest Glide Whitening Plus Scope, Crest Glide Comfort Plus and Crest Glide Shred Guard. Subjects received a pre-flossing plaque examinationiii by a trained dental examiner and were randomly assigned to a sequence of treatments. Surrogate flossing was performed by a trained dental hygienist and post-flossing plaque assessments were conduc
'/>"/>

Contact: Allison Goldstein
allison.goldstein@edelman.com
212-704-4511
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
2. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
3. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
4. Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients
5. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Clinical depression linked to abnormal emotional brain circuits
8. Preclinical study suggests organ-transplant drug may aid in lupus fight
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Good Clinical Practice Journal Awards: Winners Announced
11. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...sts offer advice on the topic of most concern to M...mpletely and finally; forsake utterly; to desert. ...s) November 24, 2009 -- Dr. Suzanne LaCombe and Dr...is its groundbreaking "The New Paradigm for 2... ( http://www.myshrink.com )., , ,Titled "Aba...
(Date:11/24/2009)...hes EyeCentral Remote Video Platform for the Secur... for Central Stations and Security Dealers. , ...r 24, 2009 -- NCL Security Launches EyeCentral Rem...nerate Recurring Monthly Revenue for Central Stati...urity systems has been and still is a great trend ...
(Date:11/23/2009)...n determined that only 663,000 of the approximatel...V) infection received antiviral therapy between 20...ng, in part because only half of the patients know...inues, by 2030 less than 15% of liver-related deat.... This study, the first to analyze nationwide pra...
(Date:11/23/2009)...gh cost of drug advertising that does little to bo...rsity of British Columbia health policy researcher... of Internal Medicine , examined the US sales patt... by the trade name Plavix used to prevent blood cl...ected to study the impact of advertising on sales ...
(Date:11/23/2009)...the problem, researchers say , , MONDAY,...ir anger over unfair treatment at work could be hu... , Men who consistently failed to express their... supervisor were more than twice as likely to have...ho vented their anger, claims a report in the Nov....
Breaking Medicine News(10 mins):Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3
...ions seen on MRIs with limited side effects, study...) -- One of the first pills to treat the "relapse-...wn to help fight the disease with few side effects... large, this doesn,t look as strong as the stronge...
...rigo Company,(Nasdaq: PRGO ; TASE) today announce.... Food and Drug Administration to manufacture and ...mg/mL. The product is comparable,to McNeil Consume...Joseph C. Papa stated, "This approval,reflects bot...
...ir shows no added benefit , , THURSDAY, Ju...r (Zovirax) doesn,t reduce the risk of HIV-1 infec... genital herpes, a U.S. study finds. , Previous re...on by two- to threefold. , In this new, randomized...
...x Competitive Bidding System for DMEPOS,Equipment,..., chair of the House Ways & Means Health Subcommit...MEPOS Competitive Acquisition Reform,Act of 2008. ...ill. In response, Bruce T. Roberts, RPh, executive...
...ternational clinical trial coordinated by the Mont...ew England Journal of Medicine . The Atrial Fibril... was a prospective, multicentre project involving ... (a very common heart rhythm disorder) further inc...
...19 /Xinhua-PRNewswire-FirstCall/ -- Benda,Pharmace...ased,pharmaceutical company producing both Gendici...the treatment of cancer, and traditional Chinese a...008. Mr. Mo joined the Board in 2007 and served as...
Other Medicine News:Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3Health News:Benda Pharmaceutical Announces Resignation of Board Member 2
(Date:11/23/2009)...PRNewswire/--Reportlinker.comannouncesthatanewmark...HolterMonitoringSystems-AGlobalMarketReview ,,...itoring-Systems---A-Global-Market-Review.html#utm_...gn=prnewswire ,, Cardiovascularmonitoringis...ientsneedtobecontinuouslymonitoredduringdiagnostic...
(Date:11/23/2009)...andNOIDA,India,Nov.23/PRNewswire-USNewswire/--Jubi...AB),andSouthernResearchInstitutetodayannouncedajoi...nnovationandenablingtechnologiesintheareasofOncolo...ueU.S.-Indiaarbitragedandleveragedpartnershipthatw...rpatientsworldwide.AMemorandumofUnderstandingwassi...
(Date:11/23/2009)...,Nov.23/PRNewswire-FirstCall/-- CumberlandPharmace...-lineresultsfromastudyevaluatingthesafetyandeffica...nhospitalizedburnpatients. ,, Statisticalsignif...verinburnpatientsoverthefirst24hoursoftreatment.Th...ddegreeburnscoveringmorethan10percenttotalbodysurf...
Breaking Medicine Technology:Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3Exercise May Prevent Prostate Cancer 3A Study 58366 1BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease 58361 1BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease 58361 2Comprehensive understanding of bacteria could lead to new insights into many organisms 10114 1Comprehensive understanding of bacteria could lead to new insights into many organisms 10114 2
Refraction System RT-2100
Ultramatic RX Master PHOROPTOR Refracting Instrument - Plus Cylinder Black
Maddox Rod, short handle (12cm)
Snellen 10' Eye Test Chart
Medicine Products: